4 result(s) for 'Multiplex'
1 - 4 of 4 results for 'Multiplex'
Sort by
Show
San Diego, CA – November 8, 2022. Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging, has acquired Cell IDx, Inc., a leader in multiplexed tissue profiling. Founded in 2012 and headquartered in San Diego, California, Cell IDx provides multiplex staining panels, tissue staining, and imaging and analysis services.
Cell IDx’s UltraPlex technology allows simultaneous detection of multiple biomarkers in many immunoassays through fluorescent and chromogenic multiplex immunohistochemistry (“IHC”) staining technology, and automated chromogenic detection of multiple markers on Leica Biosystems’ BOND RX fully automated research stainer. Together, UltraPlex and BOND RX with high throughput imaging allows researchers to detect three or more ...
Imagine the possibilities for your Chromogenic Multiplex with Leica Biosystems and Cell IDx
To accelerate the discovery journey in cancer research, Leica Biosystems has partnered with Cell IDx, a technology leader in multiplexed cellular immunodiagnostics, developing highly sensitive and specific reagents for research and clinical immunohistochemistry to meet the needs of precision medicine.
Cell IDx technology allows the automated detection of multiple markers on the BOND RX staining system. The technology uses primary antibodies from any species, employing a single antigen retrieval step that allows detection of three chromogen stains in 4.5 hours and four chromogen stains in 6 hours. The process is simple, fast, and fully automated on the BOND RX platform and Aperio Brightfi...
Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform
Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time.
“We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...
SEATTLE, USA and MELBOURNE, AUSTRALIA. March 1st Leica Biosystems continues to advance its relationship with NanoString Technologies Inc., supporting translational research to build confidence in reproducibility and throughput while minimizing manual steps and reducing hands-on time with the release of the fully automated GeoMx RNA protocol on BOND RX and BOND RXm research staining systems.
“This fully automated protocol not only increased our ability to get more slides done in a week but also increased the quality of the data coming off of our instrument by reducing variability between runs,” said Carlee Hemphill, lead scientist, CDx Labcorp Drug Development.
NanoString's GeoMx Digital Spatial Profiler uses spatial images, chemistry, and workflow to enable high-plex profiling ...